NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Candel Therapeutics, Inc. (CADL) Stock Analysis

Candel Therapeutics, Inc. (CADL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CADL

$8.37

−$0.27 (−3.13%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CADL with… →

CADL Key Statistics

As of Oct 21, 2026
Trading
Open
$8.65
Previous Close
$8.64
Day's Range
8.35–8.82
52-Week Range
4.35–14.00
Volume
1.08M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.31
Valuation
Market Cap
$709.33M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.46
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$38.18M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
76.52M
1-Year Return
+52.46%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
1.19M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CADL closed at $8.37, +52.46% over 1 year.

Candel Therapeutics, Inc. (CADL) has a market capitalization of $709.33M.

In fiscal 2025, CADL reported revenue of $0.00.

CADL Stock Return by Calendar Year

Candel Therapeutics, Inc. (CADL) return since Jul 2021: what $10,000 became

1 year
$10,000 $15,246
+52.46%
5 years
$10,000 $8,541
−14.59%
Since Jul 2021
$10,000 $11,957
+19.57%

If you had invested $10,000 in Candel Therapeutics, Inc. (CADL) at the close on July 27, 2021, the earliest close on record here, it would have been worth $11,957 at the close on October 21, 2026: +19.57% in total, +3.47% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+48.14%
2025−34.91%
2024+490.48%
2023−17.88%
2022−77.11%
2021 (partial year)+11.71%

As of October 21, 2026.

CADL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$38.18M—
2024$0.00−$55.18M—
2023$0.00−$37.94M—
2022$125.00K−$18.79M−15,035.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$48.18M−$38.18M—
2024$0.00—−$33.37M−$55.18M—
2023$0.00—−$38.39M−$37.94M—
2022$125.00K—−$34.67M−$18.79M−15,035.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Candel Therapeutics, Inc. (CADL) carries a market capitalisation of $709.33M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 55.

CADL last closed at $8.37 on October 21, 2026. That is −$0.27 (−3.13%) against the previous close. Over the past 52 weeks the price has ranged from $4.35 to $14.00. The latest close sits 92.41% above that 52-week low.

Financial Health

In fiscal 2025, Candel Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $38.18M. Trailing earnings per share are −1.46.

Across the 4 fiscal years on file, revenue moves from $125.00K in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the total return is +52.46%. Measured over 5 years, that is −3.11% a year compounded. The reported beta is −0.31. Annualized volatility over the trailing 5 years is 163.5%.

Growth & Income

No dividend is on file for CADL.

So far in 2026 the total return is +48.14%. The strongest complete calendar year on file is 2024 at +490.48%; the weakest is 2022 at −77.11%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

Candel Therapeutics, Inc. (CADL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Candel Therapeutics, Inc. CADL $709.33M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Candel Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Visit website →